Reuters logo
BRIEF-Ritter Pharma announces Phase 3 plans after end of Phase 2 meeting with FDA on RP-G28
2017年8月18日 / 下午3点47分 / 1 个月前

BRIEF-Ritter Pharma announces Phase 3 plans after end of Phase 2 meeting with FDA on RP-G28

Aug 18 (Reuters) - Ritter Pharmaceuticals Inc:

* Ritter Pharmaceuticals announces Phase 3 plans after its end of Phase 2 meeting with FDA on RP-G28 for lactose intolerance

* Has incorporated guidance from FDA on key elements of its phase 3 program to support a new drug application (NDA) for RP-G28

* Company anticipates initiating phase 3 program during first half of 2018​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below